Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Non-Current Debt (2022 - 2024)

Summit Therapeutics (SMMT) has disclosed Non-Current Debt for 3 consecutive years, with $100.0 million as the latest value for Q1 2024.

  • For the quarter ending Q1 2024, Non-Current Debt changed 0.0% year-over-year to $100.0 million, compared with a TTM value of $100.0 million through Mar 2024, changed 0.0%, and an annual FY2023 reading of $100.0 million, down 79.78% over the prior year.
  • Non-Current Debt was $100.0 million for Q1 2024 at Summit Therapeutics, roughly flat from $100.0 million in the prior quarter.
  • Across five years, Non-Current Debt topped out at $494.5 million in Q4 2022 and bottomed at $25.1 million in Q1 2022.
  • Average Non-Current Debt over 3 years is $135.0 million, with a median of $100.0 million recorded in 2023.
  • Peak annual rise in Non-Current Debt hit 299.12% in 2023, while the deepest fall reached 79.78% in 2023.
  • Year by year, Non-Current Debt stood at $494.5 million in 2022, then crashed by 79.78% to $100.0 million in 2023, then changed by 0.0% to $100.0 million in 2024.
  • Business Quant data shows Non-Current Debt for SMMT at $100.0 million in Q1 2024, $100.0 million in Q4 2023, and $100.0 million in Q2 2023.